Insider Trading Alert - BofI And 4 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Sept. 13, 2013, 141 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $99.99 to $478,779,119.37.

Highlighted Stocks Traded by Insiders:

BofI (BOFI) - FREE Research Report

Court James John who is Director at BofI sold 1,569 shares at $63.64 on Sept. 13, 2013. Following this transaction, the Director owned 4,092 shares meaning that the stake was reduced by 27.72% with the 1,569 share transaction.

The shares most recently traded at $63.89, up $0.25, or 0.39% since the insider transaction. Historical insider transactions for BofI go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 300
  • 24-Week # shares sold: 20,000

The average volume for BofI has been 208,200 shares per day over the past 30 days. BofI has a market cap of $875.9 million and is part of the financial sector and banking industry. Shares are up 128.47% year to date as of the close of trading on Friday.

BofI Holding, Inc. operates as the bank holding company for BofI Federal Bank that provides financial services to consumers through the Internet in the United States. The company's deposit products include demand accounts, savings accounts, and time deposits. The company has a P/E ratio of 22.0. Currently there is 1 analyst that rates BofI a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BOFI - FREE

TheStreet Quant Ratings rates BofI as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full BofI Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Ligand Pharmaceuticals (LGND) - FREE Research Report

Knott David M who is Director at Ligand Pharmaceuticals sold 160,000 shares at $46.78 on Sept. 13, 2013. Following this transaction, the Director owned 51,396 shares meaning that the stake was reduced by 75.69% with the 160,000 share transaction.

The shares most recently traded at $47.48, up $0.70, or 1.48% since the insider transaction. Historical insider transactions for Ligand Pharmaceuticals go as follows:

  • 4-Week # shares sold: 3,444
  • 12-Week # shares bought: 2,043
  • 12-Week # shares sold: 3,444
  • 24-Week # shares bought: 2,043
  • 24-Week # shares sold: 7,444

The average volume for Ligand Pharmaceuticals has been 257,400 shares per day over the past 30 days. Ligand Pharmaceuticals has a market cap of $951.7 million and is part of the health care sector and drugs industry. Shares are up 124.49% year to date as of the close of trading on Friday.

Ligand Pharmaceuticals Incorporated, a biotechnology company, engages in the acquisition and development of royalty revenue generating assets in the United States. The company has a P/E ratio of 125.8. Currently there are 4 analysts that rate Ligand Pharmaceuticals a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LGND - FREE

TheStreet Quant Ratings rates Ligand Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, good cash flow from operations, solid stock price performance and impressive record of earnings per share growth. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Ligand Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Theravance (THRX) - FREE Research Report

Winningham Rick E who is Chief Executive Officer at Theravance sold 22,353 shares at $40.03 on Sept. 13, 2013. Following this transaction, the Chief Executive Officer owned 690,106 shares meaning that the stake was reduced by 3.14% with the 22,353 share transaction.

The shares most recently traded at $40.87, up $0.84, or 2.06% since the insider transaction. Historical insider transactions for Theravance go as follows:

  • 12-Week # shares sold: 7,000
  • 24-Week # shares sold: 57,617

The average volume for Theravance has been 933,100 shares per day over the past 30 days. Theravance has a market cap of $4.4 billion and is part of the health care sector and drugs industry. Shares are up 85.21% year to date as of the close of trading on Friday.

Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)/pain. Currently there are 5 analysts that rate Theravance a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on THRX - FREE

TheStreet Quant Ratings rates Theravance as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally high debt management risk. Get the full Theravance Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Noble Energy (NBL) - FREE Research Report

Cook Rodney D. who is Sr. VP International at Noble Energy sold 5,000 shares at $67.00 on Sept. 13, 2013. Following this transaction, the Sr. VP International owned 128,956 shares meaning that the stake was reduced by 3.73% with the 5,000 share transaction.

The shares most recently traded at $66.19, down $0.81, or 1.22% since the insider transaction. Historical insider transactions for Noble Energy go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 5,000

The average volume for Noble Energy has been 1.6 million shares per day over the past 30 days. Noble Energy has a market cap of $24.0 billion and is part of the basic materials sector and energy industry. Shares are up 30.76% year to date as of the close of trading on Friday.

2010 volume guidance 214-217 kboepd as of 10-28-10. Gas as % of total production 62% in Q3-10. Geographic mix in Q3-10: U.S. 52%, Equatorial Guinea 21%, Israel 13%, North Sea 6%, Other 7%. The stock currently has a dividend yield of 0.84%. The company has a P/E ratio of 23.3. Currently there are 12 analysts that rate Noble Energy a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NBL - FREE

TheStreet Quant Ratings rates Noble Energy as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Noble Energy Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

TAL International Group (TAL) - FREE Research Report

Lindeberg Frederic H who is Director at TAL International Group sold 2,000 shares at $45.28 on Sept. 13, 2013. Following this transaction, the Director owned 25,100 shares meaning that the stake was reduced by 7.38% with the 2,000 share transaction.

The shares most recently traded at $45.95, up $0.67, or 1.46% since the insider transaction. Historical insider transactions for TAL International Group go as follows:

  • 4-Week # shares sold: 6,000
  • 12-Week # shares sold: 11,566
  • 24-Week # shares sold: 110,236

The average volume for TAL International Group has been 390,100 shares per day over the past 30 days. TAL International Group has a market cap of $1.5 billion and is part of the services sector and diversified services industry. Shares are up 24.52% year to date as of the close of trading on Friday.

TAL International Group, Inc. engages in leasing intermodal containers and chassis worldwide. The company operates in two segments, Equipment Leasing and Equipment Trading. The stock currently has a dividend yield of 6%. The company has a P/E ratio of 10.6. Currently there are 3 analysts that rate TAL International Group a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TAL - FREE

TheStreet Quant Ratings rates TAL International Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full TAL International Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

Halliburton, Chevron, Comcast, Agilent Technologies: 'Mad Money' Lightning Round

Halliburton, Chevron, Comcast, Agilent Technologies: 'Mad Money' Lightning Round

Your Game Plan for Next Week: Cramer's 'Mad Money' Recap (Friday 4/28/17)

Your Game Plan for Next Week: Cramer's 'Mad Money' Recap (Friday 4/28/17)

Trader's Daily Notebook: Reading the Shake-Out Through the Eyes of ETFs

Trader's Daily Notebook: Reading the Shake-Out Through the Eyes of ETFs

Here Are 4 Stocks Legendary Investor Peter Lynch Would Love

Here Are 4 Stocks Legendary Investor Peter Lynch Would Love

'Mad Money' Lightning Round: Kinder Morgan Is Coming Back

'Mad Money' Lightning Round: Kinder Morgan Is Coming Back